Last reviewed · How we verify

NCT03298256

Three-dimensional Effects of Bracing in Adolescent Idiopathic Scoliosis

Completed Last updated 24 May 2022
What this trial tests

trial testing EOS X-rays in Adolescent Idiopathic Scoliosis in 53 participants. Completed in 31 December 2021.

Timeline
1 November 2015
Primary endpoint
31 May 2019
31 December 2021

Quick facts

Lead sponsorThe University of Hong Kong
StatusCompleted
Study typeOBSERVATIONAL
Enrollment53
Start date1 November 2015
Primary completion31 May 2019
Estimated completion31 December 2021
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

The University of Hong Kong

Who can join

Adults 10 to 14, any sex, with Adolescent Idiopathic Scoliosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to investigate the three dimensional (3D) effect of bracing on the adolescent idiopathic scoliosis (AIS). In particular, it will look at the relationship between frontal deformity correction and changes in the sagittal profile and apical vertebral rotation (AVR) during bracing. The investigators hypothesise that if the thoracic frontal deformity can be controlled with bracing, there will be spontaneous correction of the sagittal plane and rotation deformity through coupling.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of EOS X-rays

Trials testing the same drug.

Other recruiting trials for Adolescent Idiopathic Scoliosis

Currently open trials in the same condition.

Other The University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03298256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing